Young Soo Rho
Young Soo Rho
The Queen's Medical Center
Dirección de correo verificada de hawaii.edu
Título
Citado por
Citado por
Año
Current trends and emerging future of indocyanine green usage in surgery and oncology: a literature review
K Polom, D Murawa, Y Rho, P Nowaczyk, M Hünerbein, P Murawa
Cancer 117 (21), 4812-4822, 2011
1992011
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet, 2020
1702020
Breast cancer sentinel lymph node mapping using near infrared guided indocyanine green and indocyanine green–human serum albumin in comparison with gamma emitting radioactive …
K Polom, D Murawa, P Nowaczyk, YS Rho, P Murawa
European Journal of Surgical Oncology (EJSO) 38 (2), 137-142, 2012
592012
Skin melanoma sentinel lymph node biopsy using real-time fluorescence navigation with indocyanine green and indocyanine green with human serum albumin
K Polom, D Murawa, YS Rho, A Spychala, P Murawa
British journal of dermatology (1951) 166 (3), 682-683, 2012
322012
Usage of invisible near infrared light (NIR) fluorescence with indocyanine green (ICG) and methylene blue (MB) in urological oncology. Part 1
W Polom, M Markuszewski, YS Rho, M Matuszewski
Central European journal of urology 67 (2), 142, 2014
272014
Use of invisible near infrared light fluorescence with indocyanine green and methylene blue in urology. Part 2
W Polom, M Markuszewski, YS Rho, M Matuszewski
Central European journal of urology 67 (3), 310, 2014
212014
Comparing clinical characteristics and outcomes of young-onset and late-onset colorectal cancer: an international collaborative study
YS Rho, M Gilabert, K Polom, A Aladashvili, K Kopeckova, V Megdanova, ...
Clinical Colorectal Cancer 16 (4), 334-342, 2017
192017
Clinical practice patterns in chemotherapeutic treatment regimens for metastatic colorectal cancer
J McLean, YS Rho, G Kuruba, A Mamo, M Gilabert, T Kavan, L Panasci, ...
Clinical colorectal cancer 15 (2), 135-140, 2016
182016
Targeted therapies provide treatment options for poorly differentiated pancreatic neuroendocrine carcinomas
M Gilabert, YS Rho, P Kavan
Oncology 92 (3), 170-172, 2017
122017
Quantifying treatment delays in adolescents and young adults with cancer at McGill University
Y Xu, M Stavrides-Eid, A Baig, M Cardoso, YS Rho, WM Shams, A Mamo, ...
Current Oncology 22 (6), e470, 2015
122015
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
M Gilabert, B Chanez, YS Rho, M Giovanini, O Turrini, G Batist, P Kavan, ...
Medicine 96 (16), 2017
102017
Adjuvant therapy for stages II and III colon cancer: risk stratification, treatment duration, and future directions
U Bender, YS Rho, I Barrera, S Aghajanyan, J Acoba, P Kavan
Current Oncology 26 (Suppl 1), S43, 2019
92019
Developments in near‐infrared‐guided hepatobiliary, pancreatic and other upper gastrointestinal surgery
D Murawa, K Polom, YS Rho, P Murawa
Contrast Media & Molecular Imaging 8 (3), 211-219, 2013
72013
Progression pattern and adverse events with bevacizumab in glioblastoma
A Mamo, A Baig, M Azam, YS Rho, S Sahebjam, T Muanza, S Owen, ...
Current Oncology 23 (5), e468, 2016
52016
Patterns and predictors of emergency department visits among older patients after breast cancer surgery: A population-based cohort study
T Westley, A Syrowatka, D Henault, YS Rho, F Khazoom, SL Chang, ...
Journal of geriatric oncology 9 (3), 204-213, 2018
42018
Complete resolution of metastatic gallbladder cancer after standard gemcitabine-cisplatin combination therapy
YS Rho, I Barrera, P Metrakos, P Kavan
Cureus 7 (12), 2015
42015
Retrospective analysis of the effect of CAPOX and mFOLFOX6 dose intensity on survival in colorectal patients in the adjuvant setting
A Mamo, J Easaw, F Ibnshamsah, A Baig, YS Rho, T Kavan, G Batist, ...
Current Oncology 23 (3), 171, 2016
32016
Canadian experience managing dose intensity of regorafenib in relation to safety and clinical outcome in metastatic colorectal cancer patients.
T Hasan, A Mamo, T Kavan, YS Rho, P Kavan
ASCO Annual Meeting Proceedings 34 (15_suppl), e15154, 2016
32016
755PPrognostic value of neutrophil-lymphocyte ratio in first line treatment for metastatic pancreatic adenocarcinoma
YS Rho, J Ranger, S Hamalova, I Barrera, A Mamo, G Batist, P Kavan
Annals of Oncology 28 (suppl_5), 2017
12017
Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients.
I Barrera, SD Filimon, J Meng, T Kavan, YS Rho, G Batist, P Kavan
Journal of Clinical Oncology 35 (4_suppl), 498-498, 2017
12017
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20